Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression

Osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is the standard treatment for patients with lung cancer harboring EGFR T790M; however, acquired resistance is inevitable due to genetic and epigenetic changes in cancer cells. In addition, a recent ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishii, Kazuya, Ohashi, Kadoaki, Watanabe, Hiromi, Makimoto, Go, Nakasuka, Takamasa, Higo, Hisao, Ninomiya, Kiichiro, Kato, Yuka, Kubo, Toshio, Rai, Kammei, Ichihara, Eiki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299008/
https://www.ncbi.nlm.nih.gov/pubmed/34386061
http://dx.doi.org/10.3892/ol.2021.12900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299008/
https://www.ncbi.nlm.nih.gov/pubmed/34386061
http://dx.doi.org/10.3892/ol.2021.12900

Ejemplares similares